INDP: Indaptus Therapeutics Inc Price to Sales
The need for colossal investments to certify living medicines creates a significant financial burden, which is reflected in the P/S ratio chart for Indaptus Therapeutics (INDP). The value of indicates the level of this metric. Stability is ensured by the streamlined distribution of biomaterials through a network of laboratories, while risk minimization is achieved through strict adherence to medical codes during the disposal of hazardous waste.
Analytical breakdowns for Indaptus (INDP)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
INDP - Company Net Income|Company Profit Forecast Indaptus Therapeutics|INDP - Price to Earnings Ratio|Future Price to Earnings Multiple Indaptus Therapeutics Inc|INDP - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Indaptus|INDP - Operating profit EBITDA|Earnings per share for the trailing year Indaptus Therapeutics|INDP - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months indaptusrx.com|INDP - Earnings per share growth in current year|Expected earnings per share trend next year Indaptus Therapeutics
- total revenue and sales volume data:
Fundamental company analysis:indaptusrx.com - INDP
For the scientific organization Indaptus Therapeutics (INDP), which focuses on immunotherapy clinical trials, the P/S multiple determines the market value of each unit of generated revenue. By analyzing the P/S chart, an investor assesses whether the asset is fundamentally overbought or possesses hidden growth potential, recognizing that low values may signal business undervaluation provided operational efficiency is maintained.
Who Indaptus Therapeutics competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Coefficient Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio KNSA|GRFS (Grifols) - P/S Multiple|Market Cap to Revenue Ratio ADPT (Adaptive Biotech)|P/S Multiple CLDX|P/S Multiple Aurinia Corp (AUPH)|Price-to-Revenue Ratio BioCryst BCRX|VERA (veratx.com) - Price-to-Sales Ratio|DNTH: Market Cap to Revenue|Pharvaris NV - Market Cap to Sales Volume|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline (TRML) - P/S Multiple|Price-to-Revenue Ratio Precigen, Inc.|pharming.com (PHAR) - Price-to-Revenue Coefficient|Market Cap to Revenue NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|Zenas Biopharma, Inc. - Market Cap to Revenue|Market Cap to Sales Volume IMNM (Immunome Bio)|Gossamer Bio, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|SEPN: P/S Multiple|Price to Sales Pieris Pharma (PVLA)|Price-to-Revenue Ratio Savara Corp|RIGL: Market Capitalization-to-Revenue Ratio|P/S Multiple ANAB|P/S Multiple astriatx.com (ATXS)|Price-to-Revenue Ratio enGene ENGN|RAPT (RAPT Therapeutics Inc.) - Price-to-Sales Ratio|Aerovate - P/S Multiple|Price to Sales Aclaris Therapeutics, Inc|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|tizianalifesciences.com (TLSA) - P/S Multiple|Market Cap to Revenue CABA|VTYX (Ventyx Biosciences Inc.) - Market Cap to Sales Volume|P/S Multiple THTX|Price-to-Revenue Coefficient Avalo Therapeutics Inc|P/S Multiple ELDN (Eledon Pharmaceuticals)|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Zura Bio Ltd ZURA|ATYR: P/S Multiple|ADAG - Price-to-Revenue Coefficient|Price-to-Revenue Ratio ImageneBio|Market Cap to Revenue Ratio STTK (Shattuck Therapeutics)|P/S Multiple EQ|connectbiopharm.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Immunic IMUX|ATRA (Atara Biotherapeutics, Inc.) - Price-to-Sales Ratio|IFRX - Price-to-Revenue Ratio|Price-to-Sales Ratio XFOR|ACET: P/S Multiple|Celularity - Market Capitalization-to-Revenue Ratio|INMB (INmune Bio Corp) - P/S Multiple|P/S Multiple Barinthus Biotherapeutics Corp|Price-to-Revenue Ratio Kezar Life Sciences (KZR)|SABS (sabbiotherapeutics.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Akari Therapeutics Plc AKTX|ENLV - Market Cap to Revenue|Q32 Bio Corp - P/S Multiple|GOVX - P/S Multiple|EDSA (Edesa Biotech, Inc.) - Market Cap to Revenue|ibioinc.com - Market Capitalization-to-Revenue Ratio|CARM (Carisma Therapeutics Inc) - P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|Market Cap to Revenue hcwbiologics.com HCWB|Price-to-Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM - Market Cap to Revenue|ADTX: Market Cap to Revenue|GRI - P/S Multiple|XORTX (XRTX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio HIND|REVB (Revelation Biosciences) - P/S Multiple|Price to Sales scinai.com SCNI|P/S Multiple CALI|Price-to-Revenue Coefficient affimed.com|Price-to-Revenue Ratio Allakos ALLK|HOOK: Market Cap to Revenue Ratio|IGM Bio - P/S Multiple|ITOS (iteostherapeutics.com) - Market Cap to Revenue Ratio|OCEA: P/S Multiple|TC BioPharm (Holdings) Plc (TCBP) - P/S Multiple|Price-to-Revenue Ratio Third Harmonic Bio, Inc
